Skip to content

Clinical Evaluation of Wanyanyu Fibronectin Lyophilized Powder Kit for Improving Facial Skin Health in Patients with Sensitive Skin

Clinical Evaluation of Wanyanyu Fibronectin Lyophilized Powder Kit for Improving Facial Skin Health in Patients with Sensitive Skin

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128241
Enrollment
Unknown
Registered
2026-07-16
Start date
2025-06-04
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensitive skin subjects

Interventions

Sensitive skin group:Wanyan Yuxian Lactoferrin Thick-Skinned Freeze-Dried Powder Set, for 28 days’ use. Area of application: face. Frequency of use: twice daily, once in the morning and once in the ev

Sponsors

The Second Affiliated Hospital of Wannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Male or female subjects aged 18 to 60 years old; 2.Subjects with dry and dehydrated facial skin; 3.Subjects with impaired skin barrier function and prone to facial flushing; 4.Subjects who are able to fully cooperate with the trial and maintain regular living habits throughout the study period; 5.Subjects capable of reading and fully understanding all contents of the informed consent form, who voluntarily sign the informed consent; 6.ubjects who agree not to use any cosmetics, medicines or health supplements that may interfere with trial results during the study period.

Exclusion criteria

Exclusion criteria: 1.Subjects with skin lesions on the test area that may interfere with the judgment of trial results; 2.Subjects with severe allergic diathesis; 3.Females who are pregnant, breastfeeding, or planning to become pregnant during the trial period; 4.Subjects with severe cardiac, hepatic or renal impairment, or severely compromised immune function; 5.Subjects with mental disorders, severe endocrine diseases, or those taking oral contraceptives; 6.Subjects who have participated in any clinical drug trial or other trials within the past 30 days, or received systemic medication that may affect trial results within the previous week; 7.Subjects who have used oral or topical cosmetic products that may interfere with trial results within the past 2 weeks; 8.Subjects unable to comply with trial requirements; 9.Subjects deemed unsuitable for participation by the investigator; 10.Other applicable exclusion criteria.

Design outcomes

Primary

MeasureTime frame
Transepidermal Water Loss;Skin chroma;Skin thickness;Moisture content;

Secondary

MeasureTime frame
sebum;Elasticity;

Countries

China

Contacts

Public ContactWu Li

The Second Affiliated Hospital of Wannan Medical College

22928304@qq.com+86 553 2871864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026